KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Payables (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Payables for 17 consecutive years, with $5.3 billion as the latest value for Q4 2025.

  • Quarterly Payables rose 2.26% to $5.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 billion through Dec 2025, up 2.26% year-over-year, with the annual reading at $5.3 billion for FY2025, 2.26% up from the prior year.
  • Payables hit $5.3 billion in Q4 2025 for Abbott Laboratories, up from $5.2 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $5.6 billion in Q1 2022 to a low of $4.8 billion in Q3 2023.
  • Historically, Payables has averaged $5.2 billion across 5 years, with a median of $5.1 billion in 2024.
  • Biggest five-year swings in Payables: grew 25.96% in 2021 and later dropped 9.42% in 2023.
  • Year by year, Payables stood at $5.2 billion in 2021, then increased by 4.87% to $5.5 billion in 2022, then decreased by 4.44% to $5.2 billion in 2023, then fell by 0.59% to $5.2 billion in 2024, then grew by 2.26% to $5.3 billion in 2025.
  • Business Quant data shows Payables for ABT at $5.3 billion in Q4 2025, $5.2 billion in Q3 2025, and $5.3 billion in Q2 2025.